Search company, investor...

Predict your next investment

LYFE Capital company logo
Venture Capital
lyfecapital.com

Investments

90

Portfolio Exits

12

Funds

4

About LYFE Capital

LYFE Capital operates as a life sciences investment firm. LYFE Capital provides capital to multi-stage companies that are primarily based throughout China and North America. The firm was founded in 2015 and is based in Jingan, Shanghai.

Headquarters Location

Park Place, 1601 West Nanjing Road Suite 3204-3205

Jingan, Shanghai, 200040,

China

(+86) 21-5220-0390

Want to inform investors similar to LYFE Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest LYFE Capital News

Kyverna Therapeutics: $145 Million Raised To Engineer New Class Of Therapies For Autoimmune Diseases

Aug 25, 2023

Kyverna Therapeutics – a clinical-stage cell therapy company with the mission of engineering a new class of therapies for autoimmune diseases – recently announced the closing of an oversubscribed $60 million Series B financing round extension, bringing the total Series B financing round to $145 million. New investors Bain Capital Life Sciences and GordonMD Global Investments LP join existing investors Gilead Sciences, Westlake Village BioPartners, Vida Ventures, Northpond Ventures, RTW Investments, Insight Partners, CAM Capital, LYFE Capital, jVen Capital, and others. Chimeric antigen receptor (CAR) T-cell therapy involves modifying a patient’s immune T cells to recognize and remove B cells in the patient’s body. And Kyverna’s anti-CD19 CAR T-cell therapies, KYV-101 and KYV-201, specifically target CD19, a protein expressed on the surface of B cells involved in various types of autoimmune diseases, including lupus nephritis. These novel therapies have the potential to offer new hope to patients who have exhausted current treatment options. And Kyverna continues to explore additional indications for its anti-CD19 CAR T-cell therapies and develop a solid pipeline of promising immunotherapies to address unmet medical needs. KEY QUOTES: “We are pleased by the increasing investor confidence in the promise of Kyverna’s anti-CD19 CAR T-cell therapy for autoimmune diseases. This Series B extension will fund Kyverna’s clinical studies in the U.S. and Europe, enabling us to move more quickly toward bringing potentially transformative and life-saving therapies to patients. We continue to treat autoimmune patients in multiple indications and multiple geographies, and we look forward to sharing clinical data in the second half of 2023.” — Ryan Jones, chief financial officer of Kyverna “I have supported anti-CD19 CAR T-cell therapy for cancer since the early clinical trials. It is exciting to see Kyverna break into new frontiers by advancing cell therapies for autoimmune diseases. I am looking forward to future developments from Kyverna.” — Craig Gordon, M.D., founder, chief executive officer, and chief investment officer of Gordon MD Global Investments LP Trending on Pulse 2.0

LYFE Capital Investments

90 Investments

LYFE Capital has made 90 investments. Their latest investment was in HSCSCI as part of their Series B - II on August 8, 2023.

CBI Logo

LYFE Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/28/2023

Series B - II

HSCSCI

$41.26M

No

2

8/3/2023

Series B - II

Kyverna Therapeutics

$60M

No

2

4/19/2023

Series B

Noah Medical

$150M

Yes

5

3/31/2023

Series B

Subscribe to see more

Subscribe to see more

0

1/18/2023

Series D

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/28/2023

8/3/2023

4/19/2023

3/31/2023

1/18/2023

Round

Series B - II

Series B - II

Series B

Series B

Series D

Company

HSCSCI

Kyverna Therapeutics

Noah Medical

Subscribe to see more

Subscribe to see more

Amount

$41.26M

$60M

$150M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

5

0

10

LYFE Capital Portfolio Exits

12 Portfolio Exits

LYFE Capital has 12 portfolio exits. Their latest portfolio exit was ImmuneOnco on September 05, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/5/2023

IPO

$99M

Public

2

8/2/2022

IPO

$99M

Public

3

3/31/2022

IPO

$99M

Public

1

12/10/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

11/15/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/5/2023

8/2/2022

3/31/2022

12/10/2021

11/15/2021

Exit

IPO

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

2

3

1

10

10

LYFE Capital Fund History

4 Fund Histories

LYFE Capital has 4 funds, including LYFE Capital Fund IV.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/22/2022

LYFE Capital Fund IV

$935M

1

10/11/2019

LYFE Capital Fund III

$99M

10

5/30/2017

LYFE Capital II

$99M

10

LYFE Capital Fund III (Phoenix)

10

Closing Date

4/22/2022

10/11/2019

5/30/2017

Fund

LYFE Capital Fund IV

LYFE Capital Fund III

LYFE Capital II

LYFE Capital Fund III (Phoenix)

Fund Type

Status

Amount

$935M

$99M

$99M

Sources

1

10

10

10

LYFE Capital Team

7 Team Members

LYFE Capital has 7 team members, including current Founder, Managing Partner, James Zhao.

Name

Work History

Title

Status

James Zhao

Founder, Managing Partner

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

James Zhao

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder, Managing Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.